Clinical responses were assessed 6 weeks after completing therapy and then after each of the 3-to 6-month intervals. The radiological response was classified according to RECIST criteria.
introduction
Therapeutic options for patients with progressive metastatic neuroendocrine carcinoma of gastroenteropancreatic origin (GEP-NET) are limited. Chemotherapy, particularly in patients with midgut GEP-NET, is not only fairly toxic but also generally ineffective [1] . When a metastatic neuroendocrine carcinoma is responsible for hormonal overproduction (i.e. carcinoid syndrome, Zollinger-Ellison Syndrome (ZES)), treatment with conventional somatostatin analogues results in symptomatic relief in the majority of cases but is rarely successful in reducing tumour size [2] [3] [4] . In those patients with extensive liver involvement, hepatic artery embolisation is indicated using particles or additional chemotherapy (though with no impact on extrahepatic disease) [5] . The unsatisfactory results of standard chemotherapy in patients with progressive metastatic GEPNETs have led to the development of peptide radionuclide radiotherapy (PRRT) [6] [7] [8] . Consequently, the recommendation of the European Neuroendocrine Tumor Society (ENETS) is that PRRT using somatostatin analogues should be considered in patients with midgut GEP-NET [9] .
The main goal of PRRT is the elimination of cancer cells using high-energy b-electrons, which have lower toxicity to the normal tissue, due to direct receptor binding [6, 7, 9] . Thus ]-octreotide (DOTATOC) Y-90 has been used most extensively [6, 7] . The data from these trials indicate that radionuclide treatment using DOTATOC Y-90 produces a partial response (PR) in 10%-35% patients, and additionally, at least 50% of patients achieve symptomatic benefit of this type of therapy [6, 7] .
A ninefold higher affinity of somatostatin subtype 2 (SST2) ]-octreotate (DOTATATE) has been found compared with DOTATOC and may therefore be preferred as a therapeutic agent [10] . In GEP patients treated with DOTATATE Lu 177, Krenning et al. confirmed a high level of efficacy exceeding that reported after DOTATOC Y-90 therapy [11] [12] [13] . 177 Lu, which has a lower tissue penetration range as compared with Y-90, might be of less benefit when treating large tumours but has lower toxicity. While it would be important to compare these two agents, a randomised trial comparing both agents is not yet possible until we have more data on the efficacy and toxicity with DOTATATE Y-90 [14] .
Thus, this study is one of the first trials to report the efficacy of DOTATATE Y-90 after at least 6 months follow-up period.
the aim of this study
The aim of this study was to determine the efficacy and toxicity of DOTATATE Y-90 in the treatment of disseminated GEP-NETs eligible or appropriate for other forms of therapy. The primary end point was assessing progression-free survival (PFS) and overall survival (OS) in long-term follow-up. 
materials and methods

patients
The group studied comprised 60 patients (28 males and 32 females), with mean age 53 years (range 23-73 years), who fulfilled the inclusion criteria such as histological diagnosis of neuroendocrine carcinomas, World Health Organization (WHO) group 2 [9] , extensive metastatic disease, evidence of clinical, biochemical [chromogranin A (CgA) and 5-hydroxy-indoleacetic acid] and/or imaging progression [computed tomography (CT) or somatostatin receptor scintigraphy (SRS)] who participated in this study. The progression was documented at least 6 months before inclusion.
somatostatin receptor scintigraphy
All patients were imaged with ]-octreotide (HYNICTOC) (Tektrotyd; Polatom, Poland) with radiotracer-avid lesions within the liver or any other part of the body having uptake equal or greater than physiological liver activity and within the abdomen and pelvis (a Krenning score ‡2) [15, 16] .
study parameters
No prior treatment with other radiolabelled somatostatin analogues was given to patients. In 24 patients receiving Sandostatin LAR 20 or 30 mg i.m., the drug was discontinued at least 4 weeks before radionuclide treatment and reintroduced 3-4 days after therapy. Exclusion criteria were as follows: haemoglobin (Hb) <8 g/dl, white blood cell <2 · 10 3 /ml, platelets <80 · 10 3 /ml, creatinine level >1.2 mg/dl or glomerular filtration rate <30 ml/min and poor performance status (WHO status 3 and 4) [17] . Contraindications towards treatment included pregnancy, established myelosuppression and renal failure.
preparation of the radiotracer
Labelling: 100 lg DOTATATE was labelled with maximum 7.5 GBq Y-90 in not more than 0.5 ml in 0.05 M HCl (Polatom) incubated at 95°C for 25 min. In all chromatography runs, radiochemical purity was >99.0%, with no need for purification. Immediately before therapy, DOTATATE Y-90 was diluted in saline to a final volume of 50 ml.
therapy-administration protocol
Ondansetron (GlaxoSmithKline, London, UK) 8 mg was administered orally 30 min before the start of infusion of 1500 ml amino acids (AAs) (Vamin 18; Fresenius Kabi, Bad Homburg, Germany), in a slow i.v. AA infusion was started 1.5 to 2 h before radiopharmaceutical administration. This volume of AA solution had nephroprotective lysine (13.5 g) and arginine (17 g) in each infusion. DOTATATE Y-90 was administered via an injection pump system together with the AA infusion in <20 min. The mean interval between therapies was 7 weeks (range 6-9 weeks). Patients were treated up to a cumulative activity of 15.2 GBq. Due to the pure beta emission of Y-90, internal dosimetry was evaluated based on previous studies using DOTATOC Y-90 treatment and carried out using Medical Internal Radiation Dose method. Using the cumulative activity as described above, the expected radiation dose to bone marrow was <2 Gy and to the kidneys <23 Gy [18] [19] [20] .
biodistribution of the radiotracer
In order to confirm that the therapeutic activity had a similar biodistribution as diagnostic SRS, 'Bremsstrahlung' images were acquired at 12-20 h after administration of DOTATATE Y-90 using a dual-head gamma camera (ecam; Siemens, Hoffman Estates, IL) equipped with high-energy collimation with a photopeak centred on 95 keV with a 50% window.
assessment of effectiveness
clinical response and performance status. Clinical response to treatment based on physical performance status and quality-of-life questionnaires (QLQ) was assessed before treatment, 6 weeks after completion of the therapy and then at three monthly intervals. The patients were assessed for clinical responses by completing a selfassessment questionnaire (European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-GI.NET 21) during physiciandirected interviews carried out before the beginning of treatment and 4-6 weeks following each treatment cycle. The items they assessed included appetite, malaise, weight loss and the presence, intensity and frequency of abdominal pain, diarrhoea, flushing, nausea, vomiting, fever, wheezing and abdominal bloating. Any analgesic and somatostatin analogue requirements before and after treatment were recorded. The patients' clinical performance status was assessed before 6 weeks and 6 months after the completion of therapy using standard WHO classification by three observers (NS, KGJ and JBC). Routine complete blood count and liver and renal function tests were measured before and then 10 and 20 days after each therapy session.
the radiological response (RECIST). Tumour size was measured by CT scan and scored, according to RECIST criteria [2] . All patients were subjected to an i.v. three-phase contrast-enhanced spiral multidetector CT.
biochemical tumour response. The biochemical tumour response was determined by serial measurements of plasma CgA, gastrin and glucagon and urine 5HIAA for patients with biologically functioning neuroendocrine tumours. Results were obtained before treatment, 6 weeks after therapy and then at three monthly intervals.
statistical analysis
OS and PFS were evaluated by using Kaplan-Meier curves, log-rank tests and Cox regression models. Comparison of OS and PFS between different groups of patients were assessed using the Cox-Mantel test. Differences in WHO or Karnofsky's performance status in patients before therapy and after completing radionuclide therapy were carried out using Wilcoxon's matched pairs test. The potential difference in response (objective and clinical) on PRRT between patients with tumours well differentiated (G1) and moderately differentiated (G2), also between primary site of the tumour, were tested using Mann-Whitney U test. P <0.05 was considered as statistically significant.
results
In the group of 60 patients, the tumour location was as follows: 25 patients, foregut; 29 patients, midgut and six patients, unknown origin (UNO) [21] . Summarised clinical information of each patient is presented in Table 1 . In Table 2 shows details of tumour pathological characteristics based on initial pT [pTNM (pathological tumour-node-metastasis) classification], grading and Ki-67 index. In Table 3 , there is presented summarised data about the previous modalities of treatment, including surgery of primary tumour and used systemic therapy including chemotherapy with different regimens and also used Sandostatin Ò LAR Ò before PRRT. A total of 180 therapies were given with a mean administered activity of 11.2 GBq (range 4.1-16.2 GBq) per patient (mean 3.7 GBq per therapy). A total of 11 patients received two cycles of treatment. These 11 patients had been administered mean activity of 6.1 GBq (range 4.1-8.4 GBq). Three of them died during therapy due to extensive progressive cancer. Another six patients received only two cycles of PRRT due to haematological toxicity. All of them had previous chemotherapy without response due to rapid disease progression (DP). Additionally, PRRT was introduced relatively quickly (within 2 months) after completing chemotherapy. Two patients had AA infusion intolerance, with severe vomiting, untreatable by i.v. ondansetron 8 mg and continued for 24 h, and declined another session of PRRT. Three cycles of PRRT were given to 38 patients and 11 patients had four cycles. The biodistribution of the DOTATATE Y-90 after therapy was visualised using the Bremsstrahlung imaging and in almost all cases perfectly matched the diagnostic 99m Tc-HYNICTOC imaging carried out before therapy.
toxicity
No major sudden acute adverse events were recorded either during the therapy session or within 24 h of DOTATATE Y-90 therapy. Mild nausea was noted in nine patients (15%) and five Annals of Oncology original article complained of vomiting, probably due to the coadministration of AA infusion in two cases as described previously. These effects disappeared spontaneously within 6 h of discontinuation of the AA infusion. In three patients with clinical carcinoid syndrome and extensive tumour load within the liver, intensive flushing occurred during and immediately after the infusion of DOTATATE Y-90. These symptoms then regressed spontaneously or significantly decreased within 6-12 h of the therapy being given; no other significant symptoms of carcinoid syndrome were noted. In four cases, there was abdominal cramping pain requiring analgesics, while two other patients complained of headaches. All the above mentioned were recorded in only a single cycle and the symptoms were not repeated in subsequent cycles. There was a single patient with glucagonoma who required 48-h hospitalisation due to hormone-related syndrome. All other patients required <24-h hospital admission, this being governed by practical and radiation protection requirements and not by the clinical state of the patient.
renal toxicity
During therapy and up to 6 months after therapy, there was no significant renal toxicity. After 12 months of completed therapy, there were three patients who had grade 2 and two others with grade 3 renal toxicity. After 24 months of followup, renal toxicity grade 2 was seen in seven patients, but no patients so far have required renal dialysis.
haematological toxicity WHO grade 3 or 4 leucopoenia was noted in five patients, Hb level <10 g/dl (WHO grade 3 or 4 toxicity) in six patients and platelet depletion in a single case (WHO grade 3). However, in a single patient, haematological toxicity with leucopoenia and anaemia was recorded at 6 weeks; two patients suffered from thrombocytopenia. Delayed toxicity occurred after 6-12 months and was seen in a single patient with low platelet count (WHO grade 3) and in two cases with anaemia. In our study, we noted a transient grade 1-2 leucopoenia, with the nadir occurring between 10 and 20 days and at 6 weeks after the DOTATATE Y-90 infusion. The details of haematological and renal toxicity are presented in Table 4 .
therapeutic activity
Radiological response assessment based on RECIST was available in 57 patients; three patients died after the second cycle of treatment before the response could be assessed. On CT imaging carried out 4-6 months after the last cycle therapy, 13 patients (23%) had a substantial reduction of tumour size, corresponding with PR, and 44 patients (77%) had stable disease (SD). One year after the completion of treatment, radiological response was evaluated in 43 patients. In 15 patients (35%) PR was documented, five patients (9%) suffered DP. One of the patient's had a DP at 6 weeks having had SD at the 6 months check. After 2 years of follow-up, tumour response was evaluated in 22 patients; five of them still had PR (23%), 11 had SD (50%) and the remaining six experienced PD (27%). Details of radiological response of all patients and those with foregut, midgut and UNO are presented in Table 5 .
biological tumour response
Nonsecretory tumours were present in 34 cases (57%). Among the secretory tumours, there were 21 cases of classical midgut carcinoid syndrome and three cases with ZES due to gastrinoma, a single glucagonoma and single tumour with mild carcinoid syndrome with a primary of UNO. There was symptomatic relief after therapy in 18 patients with secretory tumours; nine of them could stop taking somatostatin analogues for a period of between 6 and 12 months and additional six patients for a period of >12 months.
clinical benefit
Abdominal pain was reported in 24 patients before DOTATATE Y-90 therapy; 15 of these patients had pain original article Annals of Oncology reduction during therapy or 4-8 weeks after therapy. Three of the patients with reduced pain after therapy had recurrence of symptoms at 10, 18 and 19 months after the end of therapy. Nine patients reported no pain improvement after therapy, six had objective progression and two died during therapy. Of the 19 patients with diarrhoea reported before therapy, there was reduction of diarrhoea in 10 patients and in four cases, bowel movements returned to normal. Minor relief in the frequency of bowel motility was noticed in further nine patients.
Flushing was reported in 11 patients before therapy with significant reduction after therapy in nine cases. Of the 20 patients who reported loss of weight before therapy, 14 regained weight after treatment. Three patients with PD continued to suffer from weight loss.
Before therapy, there were 60% of patients with WHO status one, 37% with WHO status two and 3% with WHO status three (which though an exclusion to treatment had deterioration on treatment), and by 6 months after therapy, there was a significant improvement in clinical status with 16% patients now recorded as having WHO status of zero, 74% patients with WHO status one, 8% with WHO status two and a single patient with WHO status three (2%) (Wilcoxon matched pairs test P < 0.05). Details of the clinical response are presented in Table 6 .
PFS and OS
Median PFS calculated on the data of 57 patients was 17 months [695% confidence interval (CI) 16.4-21.2] and median OS was 22 months (695% CI 20.4-26.7)
. In eight patients with early DP, the median PFS was 4.5 months and OS 9.5 months. In those with SD or PR after 6 months, median PFS was 19.5 months (695% CI 18.6-23.1) and OS 23.5 months (695% CI 22.7-29) (Figures 1 and 2 ). There was significant difference in PFS between patients with PR, SD and PD (Cox-Mantel test P < 0.05). A significant difference in OS was noted between patients with evidence of SD or PR compared with those with PD (Cox-Mantel test P < 0.05). No significant differences were found in survival regarding secretor activity or primary site of the tumour (midgut versus foregut) (Cox-Mantel test P > 0.05). Survival rate at 2 years was 75% for all patients and 80% in those with midgut tumours and 70% in those with foregut cancers. The potential difference in median OS and PFS in patients with G1 tumours versus those with G2 tumours was tested, and there was no significant difference between these two groups. Also there was no significant difference between patients who were treated before PRRT with chemotherapy and somatostatin analogues (CoxMantel test P > 0.05).
When comparing well-differentiated tumours (G1) with moderately differentiated (G2) ones, there was a significant difference in objective response based only on RECIST criteria at 12 months of follow-up. In patients with G1 tumours, 14 patients had PR or SD and none PD; this compares with the G2 tumours where six had PR, four had DP and rest SD (MannWhitney U test P < 0.05).
Twelve clinical factors were included in the survival analysis using Cox regression models. Factors that had influence on survival are clinical response (treatment outcome) based on 
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performance status (WHO) 6 weeks after completing PRRT (P = 0.000) and the number of therapy cycles (P = 0.019). There was a nonsignificant trend in the following factors: primary tumour localisation (P = 0.052) and presence of liver involvement (P = 0.061). Among the 12 factors that could have a potential influence on the results only performance status (WHO) 6 weeks after therapy was a single independent predictor of survival with hazard rate 8.05. In those patients with WHO status zero or one, median OS was 22 months (695% CI 22.1-28.4) and in those with WHO status two, median OS was 11 months (695% CI 1.1-27.0).
discussion
Patients with neuroendocrine tumours often present with advanced and nonresectable disease and can only be offered with palliation with limited probability of success [1, 9] . The use of radionuclide therapy based on somatostatin analogues to deliver a b emitter to tumour tissues has been developed over the past 9 years [18] [19] [20] . Current ENETS recommendations indicate rational use of radiolabelled somatostatin analogues in patients with GEP-NET midgut tumours (WHO group 2). Though, in patients with foregut tumours they should be used as second-line treatment, after failure of chemotherapy [9] . Most of the published data on radiopeptide therapy of neuroendocrine tumours have used DOTATATE Y-90 and have shown an objective response of 22%-34% in for some response in tumour size reduction and 60%-65% in the case of disease stabilisation. Complete response, with disappearance of all target lesions, is seen exceptionally [6, 7, [18] [19] [20] [21] [22] [23] .
DOTATATE analogues with higher affinity towards SST2 receptors have a potential of better therapeutic efficacy. The studies with DOTATATE Lu 177 [11, 13, 18] as well as a single study using DOTATATE Y-90 [24] and another using mixture of DOTATATE Y-90 and DOTATATE Lu 177 were reported in patients with advanced GEP-NET [25] . SD was seen in 76% and there was a PR in 17%. These results were reproduced in our patients who received DOTATATE Y-90 alone, where after 6 months of follow-up using RECIST criteria a PR was seen in 23% and SD in 77% of cases. Currently there is no clear evidence that DOTATATE Y-90 is superior with DOTATATE Lu 177 or DOTATOC Y-90 [6, 7, 11, 13, [18] [19] [20] [23] [24] [25] [26] . However, direct comparison between studies is difficult as different patient groups were studied with different treatment regimens. Low objective response seen in all studies of 25% (ranging between 10% and 35%) could be related to the relative radioresistance of GEP-NETs [1, [5] [6] [7] [8] . Time ( ]-octreotate Y-90 according to patients' outcome. Patients with PR, SD and DP had significant differences on PFS using Cox-Mantel test (P < 0.05). PFS, progression-free survival; PR, partial response; SD, stable disease; DP, disease progression. ]-octreotate Y-90 according to patients' outcome. Patients with PR or SD had significant difference between those with DP on OS using Cox-Mantel test (P < 0.05). OS, overall survival; PR, partial response; SD, stable disease; DP, disease progression.
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Assessment of objective response based on RECIST or WHO remains an important standard, but in GEP tumours, there is little correlation with the benefits of therapy. The use of end points after therapy (time to PFS or OS) might be more realistic and give better guidance to the best treatment to choose [27] . The common clinical problem in extensive neuroendocrine carcinomas is related to therapeutic benefit without tumour regression, observed after PRRT. Six months after therapy, we observed therapeutic benefits in 72% of patients, in terms of general condition, and 15% of patients noted stabilisation, without further deterioration of signs and symptoms of PD. The overall clinical benefit rate was 87%, which is similar to data presented by Baum et al. [25] and Waldherr et al. [23] , who reported a 63% improvement in at least one of the four symptom categories including diarrhoea, flushing, wheezing or pellagra. In our study, reduction of abdominal pain was reported in 15 patients of 24 previously seen with a 63% rate improvement. Reduction of diarrhoea was noted in 10 of 19 patients (53% rate improvement). Reduction or disappearance of flushing was noted in 9 of 12 patients (75%).
Both the clinical and radiological response rates are identical in patients with well-differentiated (G1) tumours. The only one exception was in those patients with G1 tumours who had better results than those with G2 using RECIST criteria at 12 months. However, other radiological or clinical criteria of response rate did not differ between G1 and G2 tumours. Also, there was no significant difference between PFS and OS in both these groups of patients. Potentially, it seems to be that grading system, the mitotic count or Ki-67 index in WHO group 2 cancers had little influence on response rate after DOTATATE Y-90.
Limitation of our study is a relatively low number of patients. Except for a study by Baum et al. [25] (360 patients) and a second recently published Rotterdam trial (380 patients) [13] , most data include <100 patients [5-8, 11, 19, 23, 24] . However, neuroendocrine tumours are relatively rare and it is not possible in a single site to have enough patients to run a randomised controlled trial in PRRT.
PFS and OS were more favourable in patients with SD or PR after PRRT. Our results using Kaplan-Meier analysis are similar with regard to OS reported by Kwekkeboom et al. [13] . Interestingly, there was no significant difference in OS between patients with SD and PR, similar to the report of Rotterdam team [13] . The explanation for these results is at present unclear, so further studies including careful biological exploration of internal radiation therapy consider more biological and dosimetry data are needed, though it would seem the choice of isotope has little impact on either efficacy or toxicity. The worse prognosis in terms of OS was seen in patients with extrahepatic disease, for example, metastasis, in bone, lung or neck lymph nodes (Table 1 ). In this group of 11 patients, during clinical follow-up, eight of them died due to DP. In this group who died, six of them had increasing liver involvement.
Survival analysis using Cox regression models indicated that only WHO performance status evaluated 6 weeks after therapy was a single independent survival factor, which correlates with the finding of the Rotterdam team who have concluded the best results are obtained in those patients with a lower initial tumour load and better clinical condition. They also indicate treating those patients with limited tumour load, even if those patients had a relatively slow growing neuroendocrine tumour and no evidence of DP [13, 18] . DOTATATE Y-90 treatment was well tolerated in most patients and the reported side-effects of nausea and vomiting were probably related to the coadministration of AA infusions. The rate was similar to that mentioned in previous reports [6, 7, [18] [19] [20] [23] [24] [25] [26] . Significant haematological toxicity was noted in 10% of cases during therapy, which is similar to results obtained by Baum et al. [24, 25] , who noted significant haematological toxicity in 15% of cases, as well as McStay et al. [5] who reported haematological toxicity, due to bone marrow suppression in 13% of cases. Most authors indicated that previous chemotherapy and/or external beam radiation therapy and/or other modalities of systemic treatment including target radioisotope therapy diminished bone marrow reserves, resulting in some degree of reversible myelosuppression [13, 18-20, 23-25, 28] . It seems that patients with massive bone marrow involvement who received systemic therapy including chemo-or radionuclide therapies have an increased probability of significant haematological toxicity. In our patients, anaemia was observed in 35% of those treated previously by chemotherapy and only in 10% who were not.
Biodistribution studies demonstrated that the highest predicted absorbed doses were in the spleen, kidneys and tumour [18] . The experimental and clinical data indicated that the kidneys are the critical organs of radiopeptide therapy. Renal toxicity, due to radiation of renal cortical tissue (glomeruli), is seen in those patients treated both with Y-90-and probably less Lu 177-labelled compounds [29] . In our series, significant renal impairment (WHO grade 3 toxicity), despite routine co-infusion of positively charged AAs, was observed in two patients who developed chronic renal failure with creatinine levels between 3 and 4 mg/dl. There has been a single report also indicating end-stage damage of renal tissues after DOTATOC Y-90 therapy [30] but the problem may remain under-reported.
The additional risk factors for renal impairment due to DOTATATE Y-90 is use of previous chemotherapy, normally cisplatin and streptozocin compound. In terms of worsening of renal function with time, we did not observe significant further renal impairment in those patients who had decreased renal function during 2-3 years of continued follow-up, except in a single case who suffered worsening of renal function over time. Though the numbers with renal toxicity remain small, it would appear the rate remains similar to that reported in patients treated with DOTATOC Y-90 by Valkema et al. [31] .
conclusions DOTATATE Y-90 therapy appears to be a relatively safe and effective palliation for patients with progressive, extensive and symptomatic somatostatin receptor-positive neuroendocrine tumours.
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